



## Zymeworks Announces Participation in Upcoming Investor Conferences

January 25, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan. 25, 2023-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:

- Guggenheim Oncology Conference 2023. Zymeworks' management will participate in one-on-one meetings on February 8<sup>th</sup> – 9<sup>th</sup> and a fireside chat on February 9<sup>th</sup> at 2:10 pm Eastern Time (ET) in New York, NY.
- SVB Securities Global Biopharma Conference. Zymeworks' management will participate virtually in one-on-one meetings on February 14<sup>th</sup> – 15<sup>th</sup> and present on February 14<sup>th</sup> at 10:40 am ET.

All presentations and webcasts will be available on Zymeworks' website at <http://ir.zymeworks.com/events-and-presentations>.

### About Zymeworks Inc.

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks' wholly-owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit [www.zymeworks.com](http://www.zymeworks.com) and follow [@ZymeworksInc](https://twitter.com/ZymeworksInc) on Twitter.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230125005240/en/): <https://www.businesswire.com/news/home/20230125005240/en/>

#### Investor Inquiries:

Jack Spinks  
Associate Director, Investor Relations  
(604) 678-1388  
[ir@zymeworks.com](mailto:ir@zymeworks.com)

#### Media Inquiries:

Diana Papove  
Senior Manager, Corporate Communications  
(604) 678-1388  
[media@zymeworks.com](mailto:media@zymeworks.com)

Source: Zymeworks Inc.